IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Baird Financial Group Inc.

Baird Financial Group Inc. reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,345 shares of the company's stock after selling 46,998 shares during the period. Baird Financial Group Inc. owned approximately 0.20% of IDEXX Laboratories worth $67,533,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $31,000. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories in the fourth quarter worth approximately $38,000. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.1 %

Shares of NASDAQ IDXX opened at $471.90 on Monday. The firm has a market capitalization of $38.24 billion, a PE ratio of 44.23, a PEG ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The business has a 50-day moving average price of $419.26 and a two-hundred day moving average price of $428.06.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. During the same period in the previous year, the firm posted $2.71 earnings per share. The firm's revenue was up 3.6% on a year-over-year basis. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on IDXX shares. Piper Sandler raised their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Finally, Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a report on Monday, April 14th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $523.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.